NCT03529084 2019-11-22
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Novartis
Phase 3 Withdrawn
Clinical Trials
9 trialsNCT02795884 2016-12-30
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Yonsei University
Phase 3 Withdrawn
NCT02277457 2016-06-24
Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT01928160 2015-07-13
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT00934076 2015-05-08
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02034097 2014-05-19
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
GlaxoSmithKline
Phase 2 Withdrawn
NCT02044601 2014-04-24
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01728181 2013-07-25
A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation
University of Utah
Phase 1/2 Withdrawn
NCT00738335 2012-10-04
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
University of California, San Francisco
Phase 1 Withdrawn